Published in Rheumatol Int on December 14, 2010
Hydrogen sulfide in biochemistry and medicine. Antioxid Redox Signal (2012) 1.64
Inducible hydrogen sulfide synthesis in chondrocytes and mesenchymal progenitor cells: is H2S a novel cytoprotective mediator in the inflamed joint? J Cell Mol Med (2012) 1.14
Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications. Chem Commun (Camb) (2014) 1.03
Spa therapy: can be a valid option for treating knee osteoarthritis? Int J Biometeorol (2014) 0.87
Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med (2013) 0.84
P38 mitogen-activated protein kinase promotes dedifferentiation of primary articular chondrocytes in monolayer culture. J Cell Mol Med (2013) 0.83
May spa therapy be a valid opportunity to treat hand osteoarthritis? A review of clinical trials and mechanisms of action. Int J Biometeorol (2015) 0.79
H2S mitigates severe acute pancreatitis through the PI3K/AKT-NF-κB pathway in vivo. World J Gastroenterol (2015) 0.78
Biological signaling by small inorganic molecules. Coord Chem Rev (2016) 0.77
Hydrogen sulphide decreases IL-1β-induced activation of fibroblast-like synoviocytes from patients with osteoarthritis. J Cell Mol Med (2014) 0.76
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev (2006) 7.76
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J (2003) 4.22
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol (1993) 3.27
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett (1998) 2.61
The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J Neurochem (2004) 2.50
Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem (2002) 1.94
Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med (2006) 1.93
Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signal (2006) 1.73
The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal (2010) 1.72
Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res (2006) 1.63
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol (1993) 1.62
Pro-apoptotic effect of endogenous H2S on human aorta smooth muscle cells. FASEB J (2006) 1.62
Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1. J Biol Chem (2004) 1.56
Cytochrome oxidase inhibition induced by acute hydrogen sulfide inhalation: correlation with tissue sulfide concentrations in the rat brain, liver, lung, and nasal epithelium. Toxicol Sci (2002) 1.50
Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem Biophys Res Commun (2005) 1.48
Hydrogen sulfide induces calcium waves in astrocytes. FASEB J (2004) 1.43
Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochem Biophys Res Commun (2006) 1.31
Hydrogen sulfide-induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells. FASEB J (2006) 1.30
Hydrogen sulfide induces the synthesis of proinflammatory cytokines in human monocyte cell line U937 via the ERK-NF-kappaB pathway. J Leukoc Biol (2007) 1.30
Molecular mechanisms of hydrogen sulfide toxicity. Drug Metab Rev (2006) 1.22
p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem (2007) 1.21
Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. Biochem Biophys Res Commun (2004) 1.07
Culture of immortalized chondrocytes and their use as models of chondrocyte function. Methods Mol Med (2004) 1.07
Balneotherapy for rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.04
Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol (1996) 0.99
Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal (2008) 0.91
Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets (2006) 0.89
Immortalization of human articular chondrocytes for generation of stable, differentiated cell lines. Methods Mol Med (2004) 0.88
NF-kappaB independent activation of a series of proinflammatory genes by hydrogen sulfide. Exp Biol Med (Maywood) (2009) 0.86
H2S transiently blocks IL-6 expression in rheumatoid arthritic fibroblast-like synoviocytes and deactivates p44/42 mitogen-activated protein kinase. Cell Biol Int (2010) 0.83
Taking baths: the efficacy of balneotherapy in patients with arthritis. A systematic review. J Rheumatol (1997) 0.82
Balneotherapy for rheumatoid arthritis and osteoarthritis. Cochrane Database Syst Rev (2000) 0.81
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Peripheral Nerves in Chronic Atrophic Arthritis. Am J Pathol (1942) 5.21
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Lesions of Skeletal Muscles in Rheumatoid Arthritis: Nodular Polymyositis. Am J Pathol (1946) 4.86
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med (1978) 2.92
NODULAR POLYMYOSITIS IN RHEUMATOID ARTHRITIS. Science (1945) 2.59
Mixed connective tissue disease: to be or not to be? Arthritis Rheum (1998) 2.58
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest (1995) 2.33
Identification of a site on 23S ribosomal RNA located at the peptidyl transferase center. Proc Natl Acad Sci U S A (1984) 2.22
Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes (1993) 1.78
Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol (1991) 1.78
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis (2005) 1.77
The reliability of analysis of intraoperative frozen sections for identifying active infection during revision hip or knee arthroplasty. J Bone Joint Surg Am (1996) 1.77
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.61
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain. Proc Natl Acad Sci U S A (1987) 1.48
Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol (1990) 1.47
Thy-1+ dendritic epidermal cells belong to the T-cell lineage. Proc Natl Acad Sci U S A (1987) 1.46
Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) (2008) 1.46
Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol (1994) 1.44
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Autoimmune reactions in patients with silicone breast implants. Wien Klin Wochenschr (1996) 1.39
Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med (1978) 1.38
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest (1999) 1.35
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie (2002) 1.28
Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum (2001) 1.25
Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol (1993) 1.20
Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli. Nucleic Acids Res (1997) 1.20
Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis (1994) 1.17
Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol (1986) 1.16
Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol (2001) 1.15
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest (1997) 1.14
Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. J Lipid Res (1995) 1.13
Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis (2009) 1.10
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care (1996) 1.10
Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood (1994) 1.10
Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum (1995) 1.09
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest (1996) 1.09
The heterogeneous nuclear ribonucleoproteins I and K interact with a subset of the ro ribonucleoprotein-associated Y RNAs in vitro and in vivo. J Biol Chem (2001) 1.09
Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum (2012) 1.07
Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. Arthritis Rheum (2001) 1.07
Maturational steps of bone marrow-derived dendritic murine epidermal cells. Phenotypic and functional studies on Langerhans cells and Thy-1+ dendritic epidermal cells in the perinatal period. J Immunol (1989) 1.07
The stressed synovium. Arthritis Res (2001) 1.07
Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol (1998) 1.06
Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum (2001) 1.06
Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate (1998) 1.06
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol (2000) 1.05
Heterogeneity of primary lipoprotein lipase deficiency. Metabolism (1980) 1.05
Infrared and Raman imaging of biological and biomimetic samples. Fresenius J Anal Chem (2001) 1.05
Nature of the familial influence on plasma lipid levels. Atherosclerosis (1979) 1.04
Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) (2001) 1.03
Characterizing the performance of two optical particle counters (Grimm OPC1.108 and OPC1.109) under urban aerosol conditions. J Aerosol Sci (2010) 1.02
TNFalpha mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF1/hsp70 stress response. Cell Death Differ (2003) 1.02
Analysis of the molecular composition of Ro ribonucleoprotein complexes. Identification of novel Y RNA-binding proteins. Eur J Biochem (2000) 1.02
Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus (2002) 1.02
Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol (1999) 1.02
Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J (1999) 1.02
Resistance to insulin but not to glucagon in lean human hypertriglyceridemics. Diabetes (1980) 1.01
Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population. Can Med Assoc J (1980) 1.00
Recurrent hypoglycemia secondary to drug-dispensing error. Arch Intern Med (1991) 1.00
Details of gastropod phylogeny inferred from 18S rRNA sequences. Mol Phylogenet Evol (1998) 1.00
Lipoprotein lipase in fat-induced hyperlipemia. N Engl J Med (1968) 0.99
Periosteal chondroma. A report of ten cases and review of the literature. Clin Orthop Relat Res (1990) 0.99
Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P. Nucleic Acids Res (1998) 0.99
Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis (2000) 0.98
The effects of prolonged fasting on plasma triglyceride kinetics in man. Metabolism (1977) 0.98
Anti-cytokine therapy in systemic lupus erythematosus. Lupus (2005) 0.96
Are autoantibodies active players or epiphenomena? Curr Opin Rheumatol (1998) 0.96
Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocyte-macrophage lineage antigens. J Clin Invest (1983) 0.96
Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus (2013) 0.95
Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum (2001) 0.95
Improved method for quantitation of B apoprotein in plasma lipoproteins by electroimmunoassay. Clin Chem (1981) 0.95
Prognostic value of blood-vessel invasion in cervical cancer. Obstet Gynecol (1967) 0.94
Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats. J Lipid Res (1997) 0.93
Diabetes and atherosclerosis: an overview. Diabetes (1981) 0.93
Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med (1979) 0.93
Epidermal cells as accessory cells in the generation of allo-reactive and hapten-specific cytotoxic T lymphocyte (CTL) responses. J Immunol (1985) 0.92
Turnover and recycling of glucose in man during prolonged fasting. Metabolism (1977) 0.92
Laboratory standardization of a large international clinical trial: the DAIS experience. DAIS Project Group. Diabetes Atherosclerosis Intervention Study. Clin Biochem (2000) 0.92
Normative standards of plasma cholesterol and triglyceride concentrations in Canadians of working age. Can Med Assoc J (1977) 0.92
Milk and plasma lipid composition in a lactating patient with type I hyperlipoproteinemia. Am J Clin Nutr (1985) 0.92
The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol (1996) 0.91
Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med (1976) 0.91
Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. Int Immunol (2001) 0.91
A stable isotope method using a [(2)H(5)]glycerol bolus to measure very low density lipoprotein triglyceride kinetics in humans. J Lipid Res (1999) 0.91
Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev (1996) 0.91
Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H6]ethanol. J Lipid Res (1996) 0.91
Brown and white adipose tissue metabolism response to norepinephrine and insulin. Am J Physiol (1966) 0.91
Long-term study of cloud condensation nuclei (CCN) activation of the atmospheric aerosol in Vienna. Atmos Environ (1994) (2011) 0.91
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis (2007) 0.91
The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia. Metabolism (1982) 0.90